Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth K Lee

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Clinical Advances in Hematology & Oncology : H&O|August 7, 2024
Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapiesElizabeth K Lee, Joyce F Liu
Cancer Treatment and Research|November 17, 2023
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted AgentsElizabeth K Lee, Joyce F Liu
Trends in Cancer|September 3, 2019
Combined PARP and Immune Checkpoint Inhibition in Ovarian CancerElizabeth K Lee, Panagiotis A Konstantinopoulos
Gynecologic Oncology|April 2, 2019
Antibody-drug conjugates in gynecologic malignanciesElizabeth K Lee, Joyce F Liu
Cancers|July 30, 2020
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination TherapiesElizabeth K Lee, Ursula A Matulonis
Therapeutic Advances in Medical Oncology|August 13, 2020
PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancersElizabeth K Lee, Panagiotis A Konstantinopoulos
Expert Opinion on Emerging Drugs|June 23, 2020
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitorsElizabeth K Lee, Ursula A Matulonis
Gynecologic Oncology|November 8, 2020
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapiesElizabeth K Lee, Amanda N Fader, Alessandro D Santin, et al.
Gynecologic Oncology|March 21, 2025
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancersElizabeth K Lee, David L Kolin, Ursula A Matulonis, et al.
Gynecologic Oncology Reports|February 9, 2019
<i>POLE</i>-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposureElizabeth K Lee, Neal I Lindeman, Ursula A Matulonis, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Clinical Advances in Hematology & Oncology : H&O|August 7, 2024
Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapiesElizabeth K Lee, Joyce F Liu
Cancer Treatment and Research|November 17, 2023
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted AgentsElizabeth K Lee, Joyce F Liu
Trends in Cancer|September 3, 2019
Combined PARP and Immune Checkpoint Inhibition in Ovarian CancerElizabeth K Lee, Panagiotis A Konstantinopoulos
Gynecologic Oncology|April 2, 2019
Antibody-drug conjugates in gynecologic malignanciesElizabeth K Lee, Joyce F Liu
Cancers|July 30, 2020
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination TherapiesElizabeth K Lee, Ursula A Matulonis
Therapeutic Advances in Medical Oncology|August 13, 2020
PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancersElizabeth K Lee, Panagiotis A Konstantinopoulos
Expert Opinion on Emerging Drugs|June 23, 2020
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitorsElizabeth K Lee, Ursula A Matulonis
Gynecologic Oncology|November 8, 2020
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapiesElizabeth K Lee, Amanda N Fader, Alessandro D Santin, et al.
Gynecologic Oncology|March 21, 2025
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancersElizabeth K Lee, David L Kolin, Ursula A Matulonis, et al.
Gynecologic Oncology Reports|February 9, 2019
<i>POLE</i>-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposureElizabeth K Lee, Neal I Lindeman, Ursula A Matulonis, et al.
Pageof 4